Related references
Note: Only part of the references are listed.Regulation of matrix metalloproteinase activity in health and disease
Elin Hadler-Olsen et al.
FEBS JOURNAL (2011)
Localizing matrix metalloproteinase activities in the pericellular environment
Gillian Murphy et al.
FEBS JOURNAL (2011)
Reduction of Hyaluronan-CD44-Mediated Growth, Migration, and Cisplatin Resistance in Head and Neck Cancer Due to Inhibition of Rho Kinase and PI-3 Kinase Signaling
Carlos Torre et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2010)
The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity
Keith Brew et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2010)
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kai Kessenbrock et al.
CELL (2010)
Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting
Achilleas D. Theocharis et al.
FEBS JOURNAL (2010)
Plasticity of cell migration: a multiscale tuning model
Peter Friedl et al.
JOURNAL OF CELL BIOLOGY (2010)
Higher sensitivity of Adamts12-deficient mice to tumor growth and angiogenesis
M. El Hour et al.
ONCOGENE (2010)
Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis
Laetitia Devy et al.
CANCER RESEARCH (2009)
Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies
Ch. Gialeli et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition
Carl-Henrik Heldin et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Matrix Metalloproteinases As Novel Biomarkers and Potential Therapeutic Targets in Human Cancer
Roopali Roy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Basement membrane proteoglycans: Modulators Par Excellence of cancer growth and angiogenesis
Renato V. Iozzo et al.
MOLECULES AND CELLS (2009)
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Kornelia Polyak et al.
NATURE REVIEWS CANCER (2009)
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer
N. Rocks et al.
BIOCHIMIE (2008)
Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer
J. T. Korpi et al.
BRITISH JOURNAL OF CANCER (2008)
Tumor-associated MICA is shed by ADAM proteases
Inja Waldhauer et al.
CANCER RESEARCH (2008)
Matrix metalloproteinase inhibitors as anticancer agents
Panagiotis A. Konstantinopoulos et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
Progress in matrix metalloproteinase research
Gillian Murphy et al.
MOLECULAR ASPECTS OF MEDICINE (2008)
Estradiol-estrogen receptor: A key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells
Olga Ch. Kousidou et al.
MOLECULAR ONCOLOGY (2008)
Matrix metalloproteinases at cancer tumor-host interface
Agnes Noel et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
MMPs as therapeutic targets - Still a viable option?
Barbara Fingleton
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
The ADAMs: signalling scissors in the tumour microenvironment
Gillian Murphy
NATURE REVIEWS CANCER (2008)
Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis
Veronica C. Ardi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Tumour micro environment -: Opinion -: Emerging roles of proteases in tumour suppression
Carlos LOpez-Otin et al.
NATURE REVIEWS CANCER (2007)
The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells
V. Kirkin et al.
CELL DEATH AND DIFFERENTIATION (2007)
Triple-helical transition state analogues: A new class of selective matrix metalloproteinase inhibitors
Janelle Lauer-Fields et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer
Jordan S. Fridman et al.
CLINICAL CANCER RESEARCH (2007)
Matrix metalloproteinases and the regulation of tissue remodelling
Andrea Page-McCaw et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Epilysin (MMP-28) induces TGF-β mediated epithelial to mesenchymal transition in lung carcinoma cells
Sara A. Illman et al.
JOURNAL OF CELL SCIENCE (2006)
Invadopodia: specialized cell structures for cancer invasion
Alissa M. Weaver
CLINICAL & EXPERIMENTAL METASTASIS (2006)
Matrix metalloproteinases and tumor metastasis
EI Deryugina et al.
CANCER AND METASTASIS REVIEWS (2006)
Structure and function of matrix metalloproteinases and TIMPs
H Nagase et al.
CARDIOVASCULAR RESEARCH (2006)
Tetracyclines: Nonantibiotic properties and their clinical implications
AN Sapadin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Recent advances in understanding the mechanism of action of bisphosphonates
Fraser P. Coxon et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability
M Nakamura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and, β-catenin translocation
T Maretzky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Matrix metalloproteinase inhibitors as anticancer therapeutics
F Mannello et al.
CURRENT CANCER DRUG TARGETS (2005)
Antimetastatic activity of a novel mechanism-based gelatinase inhibitor
A Krüger et al.
CANCER RESEARCH (2005)
siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line
XL Jiang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2005)
Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs
P Cuniasse et al.
BIOCHIMIE (2005)
Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells
S Strand et al.
ONCOGENE (2004)
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer
KD Miller et al.
CLINICAL CANCER RESEARCH (2004)
Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands
U Sahin et al.
JOURNAL OF CELL BIOLOGY (2004)
Matrix metalloproteinases as modulators of inflammation and innate immunity
WC Parks et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group Trial E2196
JA Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-αv integrin regulates cross-talk between αvβ3 and α2β1 integrins in breast carcinoma cells
PC Baciu et al.
EXPERIMENTAL CELL RESEARCH (2003)
Loss of collagenase-2 confers increased skin tumor susceptibility to male mice
M Balbín et al.
NATURE GENETICS (2003)
Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells
TN Mitropoulou et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma
XL Jiang et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2003)
Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury
QL Li et al.
CELL (2002)
The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1
DZ Mu et al.
JOURNAL OF CELL BIOLOGY (2002)
CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling
WH Yu et al.
GENES & DEVELOPMENT (2002)
New functions for the matrix metalloproteinases in cancer progression
M Egeblad et al.
NATURE REVIEWS CANCER (2002)
Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
L Gorelik et al.
NATURE MEDICINE (2001)
Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo
JS Xu et al.
JOURNAL OF CELL BIOLOGY (2001)
In vivo molecular target assessment of matrix metalloproteinase inhibition
C Bremer et al.
NATURE MEDICINE (2001)
Development of matrix metalloproteinase inhibitors in cancer therapy
M Hidalgo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of pro-MMP-2
M Toth et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Marimastat: the clinical development of a matrix metalloproteinase inhibitor
AL Thomas et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000)
ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3
F Loechel et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
G Bergers et al.
NATURE CELL BIOLOGY (2000)
Ongoing trials with matrix metalloproteinase inhibitors
PD Brown
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000)
Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5
N Koshikawa et al.
JOURNAL OF CELL BIOLOGY (2000)